Downregulation of lncRNA H19 alleviates atherosclerosis through inducing the apoptosis of vascular smooth muscle cells

Sun,Hui; Jiang,Qianqian; Sheng,Li; Cui,Kai

doi:10.3892/mmr.2020.11394

Downregulation of lncRNA H19 alleviates atherosclerosis through inducing the apoptosis of vascular smooth muscle cells

Authors:
- Hui Sun
- Qianqian Jiang
- Li Sheng
- Kai Cui
View Affiliations

Affiliations: Department of Cardiology, Jining First People's Hospital, Jining, Shandong 272100, P.R. China, Department of Cardiology, The Second People's Hospital of Liaocheng, Linqing, Liaocheng, Shandong 252601, P.R. China, Geriatrics Department, The Central Hospital of Shengli Oilfield, Dongying, Shandong 257034, P.R. China
Published online on: July 31, 2020 https://doi.org/10.3892/mmr.2020.11394
Pages: 3095-3102
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aberrant proliferation and apoptosis of vascular smooth muscle cells (VSMCs) serve a dominant role in the pathogenesis of atherosclerosis (AS). Long non‑coding (lnc)RNA H19 is reported to accelerate the progression of AS by inhibiting the apoptosis of VSMCs, whereas p53 is identified as promoting VSMC apoptosis. The present study aimed to explore the effects of H19/p53 on the pathogenesis of AS. Apolipoprotein E knockout (ApoE‑/‑) mice fed a high‑fat diet were used as in vivo AS models. Reverse transcription‑quantitative PCR and western blot were used to detect mRNA and protein expression levels, respectively. VSMC proliferation and apoptosis were respectively assessed by CCK‑8 and flow cytometry. Compared with the control group, mouse weight and plaque area were all increased in the AS model group, as was the expression of H19. Knockdown of H19 reduced the proliferation and induced apoptosis of VSMCs, and increased the expression of p53, cleaved caspase3 (c‑caspase3) and p53 upregulated modulator of apoptosis, as well as enhancing the interaction between Bax and p53 proteins. Downregulation of H19 reduced the plaque area and promoted the expression of c‑caspase3 in mouse aortic tissues in vivo, as well as enhancing the effects of simvastatin, a drug used for AS treatment. Results from the present study indicated that knockdown of H19 may prevent AS deterioration through increased p53‑mediated VSMC apoptosis.

View Figures

View References

1	Schaftenaar F, Frodermann V, Kuiper J and Lutgens E: Atherosclerosis: The interplay between lipids and immune cells. Curr Opin Lipdol. 27:3095–215. 2016.
2	Weber C and Noels H: Atherosclerosis: Current pathogenesis and therapeutic options. Nat Med. 17:1410–1422. 2011. View Article : Google Scholar : PubMed/NCBI
3	Moore KJ, Sheedy FJ and Fisher EA: Macrophages in atherosclerosis: A dynamic balance. Nat Rev Immunol. 13:709–721. 2013. View Article : Google Scholar : PubMed/NCBI
4	Galkina E and Ley K: Immune and inflammatory mechanisms of atherosclerosis. Ann Rev Immunol. 27:165–197. 2009. View Article : Google Scholar
5	Leischik R, Foshag P, Straub M, Garg P, Dworrak B, Littwitz H, Lazic JS and Horlitz M: Physical activity, cardiorespiratory fitness and carotid intima thickness: Sedentary occupation as risk factor for atherosclerosis and obesity. Eur Rev Med Pharmacol Sci. 19:3157–3168. 2015.PubMed/NCBI
6	Bennett MR, Sinha S and Owens GK: Vascular smooth muscle cells in atherosclerosis. Circ Res. 118:692–702. 2016. View Article : Google Scholar : PubMed/NCBI
7	Kapranov P, Willingham AT and Gingeras TR: Genome-wide transcription and the implications for genomic organization. Nat Rev Genet. 8:413–423. 2007. View Article : Google Scholar : PubMed/NCBI
8	Yang JX, Rastetter RH and Wilhelm D: Non-coding RNAs: An introduction. Adv Exp Med Biol. 886:13–32. 2016. View Article : Google Scholar : PubMed/NCBI
9	Rinn JL and Chang HY: Genome regulation by long noncoding RNAs. Ann Rev Biochem. 81:145–166. 2012. View Article : Google Scholar : PubMed/NCBI
10	Huarte M: The emerging role of lncRNAs in cancer. Nat Med. 21:1253–1261. 2015. View Article : Google Scholar : PubMed/NCBI
11	Lorenzen JM and Thum T: Long noncoding RNAs in kidney and cardiovascular diseases. Nat Rev Nephrol. 12:360–373. 2016. View Article : Google Scholar : PubMed/NCBI
12	Zhou T, Ding JW, Wang XA and Zheng XX: Long noncoding RNAs and atherosclerosis. Atherosclerosis. 248:51–61. 2016. View Article : Google Scholar : PubMed/NCBI
13	Jian L, Jian D, Chen Q and Zhang L: Long noncoding RNAs in atherosclerosis. J Atheroscler Thromb. 23:376–384. 2016. View Article : Google Scholar : PubMed/NCBI
14	Kallen AN, Zhou XB, Xu J, Qiao C, Ma J, Yan L, Lu L, Liu C, Yi JS, Zhang H, et al: The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell. 52:101–112. 2013. View Article : Google Scholar : PubMed/NCBI
15	Pan JX: LncRNA H19 promotes atherosclerosis by regulating MAPK and NF-kB signaling pathway. Eur Rev Med Pharmacol Sci. 21:322–328. 2017.PubMed/NCBI
16	Guevara NV, Kim HS, Antonova EI and Chan L: The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat Med. 5:335–339. 1999. View Article : Google Scholar : PubMed/NCBI
17	Merched AJ, Williams E and Chan L: Macrophage-specific p53 expression plays a crucial role in atherosclerosis development and plaque remodeling. Arterioscler Thromb Vasc Biol. 23:1608–1614. 2003. View Article : Google Scholar : PubMed/NCBI
18	van Vlijmen BJ, Gerritsen G, Franken AL, Boesten LS, Kockx MM, Gijbels MJ, Vierboom MP, van Eck M, van De Water B, van Berkel TJ and Havekes LM: Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ Res. 88:780–786. 2001. View Article : Google Scholar : PubMed/NCBI
19	Mercer J and Bennett M: The role of p53 in atherosclerosis. Cell Cycle. 5:1907–1909. 2006. View Article : Google Scholar : PubMed/NCBI
20	Mercer J, Figg N, Stoneman V, Braganza D and Bennett MR: Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout mice. Circ Res. 96:667–674. 2005. View Article : Google Scholar : PubMed/NCBI
21	Wu G, Cai J, Han Y, Chen J, Huang ZP, Chen C, Cai Y, Huang H, Yang Y, Liu Y, et al: LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity. Circulation. 130:1452–1465. 2014. View Article : Google Scholar : PubMed/NCBI
22	Ma L, Qian L, Ying Q, Zhang Y, Zhou C and Wu G: I4, a synthetic anti-diabetes agent, attenuates atherosclerosis through its lipid-lowering, anti-inflammatory and anti-apoptosis properties. Mol Cell Endocrinol. 440:80–92. 2017. View Article : Google Scholar : PubMed/NCBI
23	Yin M, Liu Q, Yu L, Yang Y, Lu M, Wang H, Luo D, Rong X, Tang F and Guo J: Downregulations of CD36 and calpain-1, inflammation, and atherosclerosis by simvastatin in apolipoprotein E knockout mice. J Vasc Res. 54:123–130. 2017. View Article : Google Scholar : PubMed/NCBI
24	Xin B, He X, Wang J, Cai J, Wei W, Zhang T and Shen X: Nerve growth factor regulates CD133 function to promote tumor cell migration and invasion via activating ERK1/2 signaling in pancreatic cancer. Pancreatology. 16:1005–1014. 2016. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Gorenne I, Kumar S, Gray K, Figg N, Yu H, Mercer J and Bennett M: Vascular smooth muscle cell sirtuin 1 protects against DNA damage and inhibits atherosclerosis. Circulation. 127:386–396. 2013. View Article : Google Scholar : PubMed/NCBI
27	Rudijanto A: The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Med Indones. 39:86–93. 2007.PubMed/NCBI
28	Clarke MC, Figg N, Maguire JJ, Davenport AP, Goddard M, Littlewood TD and Bennett MR: Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med. 12:1075–1080. 2006. View Article : Google Scholar : PubMed/NCBI
29	Clarke MC, Littlewood TD, Figg N, Maguire JJ, Davenport AP, Goddard M and Bennett MR: Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcification and medial degeneration. Circ Res. 102:1529–1538. 2008. View Article : Google Scholar : PubMed/NCBI
30	Chen C, Cheng G, Yang X, Li C, Shi R and Zhao N: Tanshinol suppresses endothelial cells apoptosis in mice with atherosclerosis via lncRNA TUG1 up-regulating the expression of miR-26a. Am J Transl Res. 8:2981–2991. 2016.PubMed/NCBI
31	Yao X, Yan C, Zhang L, Li Y and Wan Q: LncRNA ENST00113 promotes proliferation, survival, and migration by activating PI3K/Akt/mTOR signaling pathway in atherosclerosis. Medicine (Baltimore). 97:e04732018. View Article : Google Scholar : PubMed/NCBI
32	Wassmann S, Wassmann K, Jung A, Velten M, Knuefermann P, Petoumenos V, Becher U, Werner C, Mueller C and Nickenig G: Induction of p53 by GKLF is essential for inhibition of proliferation of vascular smooth muscle cells. J Mol Cell Cardiol. 43:301–307. 2007. View Article : Google Scholar : PubMed/NCBI
33	Song G, Liu J, Zhao Z, Yu Y, Tian H, Yao S, Li G and Qin S: Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet. Lipids Health Dis. 10:82011. View Article : Google Scholar : PubMed/NCBI
34	Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang PR, Zhang D, et al: Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 21:115–121. 2001. View Article : Google Scholar : PubMed/NCBI
35	Zhang Z, Zhang M, Li Y, Liu S, Ping S, Wang J, Ning F, Xie F and Li C: Simvastatin inhibits the additive activation of ERK1/2 and proliferation of rat vascular smooth muscle cells induced by combined mechanical stress and oxLDL through LOX-1 pathway. Cell Signal. 25:332–340. 2013. View Article : Google Scholar : PubMed/NCBI
36	Chan KC, Wang CJ, Ho HH, Chen HM and Huang CN: Simvastatin inhibits cell cycle progression in glucose-stimulated proliferation of aortic vascular smooth muscle cells by up-regulating cyclin dependent kinase inhibitors and p53. Pharmacol Res. 58:247–256. 2008. View Article : Google Scholar : PubMed/NCBI